#United States #New York #Class Action #Gross Law Firm #Skye Bioscience

Important Notice to Skye Bioscience Shareholders

The Gross Law Firm has recently thrown light on a significant legal development concerning Skye Bioscience, Inc. (NASDAQ: SKYE). According to the latest announcement, shareholders need to be informed about a pending class action lawsuit aimed at addressing potential grievances related to the company's stock performance and misleading statements made to investors.

Class Action Background

Shareholders who acquired shares of Skye Bioscience during a defined class period from November 4, 2024, to October 3, 2025, are encouraged to pay close attention. The allegations state that the company and its executives may have been involved in disseminating false information regarding their lead product candidate, nimacimab. Claims have been put forth suggesting that nimacimab's effectiveness might not align with the representations made to investors, causing their subsequent public statements to be misleading at various stages.

Allegations Against the Company

The key grievances raised in the complaint emphasize three critical points:
1. Misleading Statements: It is alleged that Skye Bioscience officials provided inaccurate information regarding nimacimab’s effectiveness, possibly leading to inflated expectations among investors.
2. Overstated Prospects: Concerns have been raised regarding the overestimation of the clinical, regulatory, and commercial possibilities surrounding nimacimab, which could have misled stakeholders.
3. Material Omission: The complaint highlights the failure to disclose critical details about nimacimab that could impact investor decisions significantly.

Important Deadlines for Investors

As part of the ongoing proceedings, it is crucial for impacted shareholders to note January 16, 2026, as the lead plaintiff deadline. Interested individuals must register to participate in the class action litigation process. The Gross Law Firm seeks to engage with all shareholders who bought SKYE shares during the specified timeframe. Those wanting to consider applying for lead plaintiff status are encouraged to initiate contact soon.

Registration Process and Benefits

By registering with the Gross Law Firm, shareholders will be entitled to a complimentary portfolio monitoring service that updates them on the status of the case. This step is essential to ensure that they remain informed regarding the evolution of the lawsuit, which aims to recover losses purportedly incurred due to the alleged misleading actions of Skye Bioscience.

The Role of the Gross Law Firm

The Gross Law Firm stands as a nationally recognized name in class action lawsuits, committed to safeguarding the rights of investors. Their mission focuses on addressing instances of deceit, fraud, or illegal business operations that have historically impacted shareholders. By choosing to represent investors in this matter, they work towards ensuring transparency and accountability in corporate practices that might have led to deterioration in Skye Bioscience’s stock value.

Final Thoughts

As the deadline approaches, it’s essential for shareholders of Skye Bioscience, Inc. to act promptly to determine their eligibility and options for participation in this significant class action lawsuit. The Gross Law Firm emphasizes the importance of collective action in response to potential corporate misconduct and reassures that joining this class action comes without any cost or obligation to the participating investors.

For further queries, investors can reach out to the Gross Law Firm at their New York office or via their online contact form.

• ---

Contact Information:
The Gross Law Firm
15 West 38th Street, 12th Floor
New York, NY 10018
Email: [email protected]
Phone: (646) 453-8903

_This advisory is intended for informational purposes only, and previous results do not guarantee similar outcomes._